Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study-Reference-Cited by-同舟云学术

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study

Published:2022-07-13 Issue:4 Volume:109 Page:373-380
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Del Giudice Maria Livia¹^ORCID,Gozzetti Alessandro²,Antonioli Elisabetta³,Attucci Irene³,Pengue Ludovica³,Cassano Cassano Raffaella¹,Ghio Francesco¹,Orciuolo Enrico¹,Simoncelli Martina²,Bocchia Monica²,Galimberti Sara¹,Buda Gabriele¹^ORCID

Affiliation:

1. Department of Clinical and Experimental Medicine, Hematology University of Pisa Pisa Italy

2. Hematology, Azienda Ospedaliera Universitaria Senese University of Siena Siena Italy

3. Hematology, Careggi Hospital University of Florence Florence Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13819

Reference26 articles.

1. Global Burden of Multiple Myeloma

2. Myeloma: Surveillance Epidemiology and End Results Program: SEER Stats Facts Sheet—Myeloma. Accessed February 13 2022.https://seer.cancer.gov/statfacts/html/mulmy.html

3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19

2. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study);Future Oncology;2024-02-29

3. Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland;eJHaem;2023-10-06

4. Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203);Journal of Cancer Research and Clinical Oncology;2023-09-12

5. Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: Catholic Research Network for Multiple Myeloma Study (CARE-MM 2203);2023-04-07